Creso Pharma Limited (COPHF)
USD 0.12
(0.0%)
USD 0.12
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.14 Million | -17.3 Million | -22.37 Million | -9.62 Million | -10.16 Million | -8.1 Million |
| Net Income | -52.44 Million | -32.78 Million | -30.03 Million | -30.77 Million | -15.05 Million | -16.75 Million |
| Depreciation & Amortization | 2.02 Million | 2.57 Million | 846 Thousand | 345.11 Thousand | 397.95 Thousand | 38.72 Thousand |
| Deferred income taxes | - | - | 84.00 | - | - | - |
| Stock-based compensation | 7.54 Million | 3.33 Million | 8.25 Million | 8.36 Million | 2.35 Million | 7.09 Million |
| Change in working capital | 4.13 Million | -1.58 Million | 1.1 Million | 1.94 Million | -1.88 Million | -424.99 Thousand |
| Other non-cash items | 30.59 Million | 11.15 Million | -2.55 Million | 10.5 Million | 4.01 Million | 1.87 Million |
| Investing Cash Flow | -81 Thousand | -2.28 Million | -1.37 Million | -831.68 Thousand | -3.34 Million | -4.21 Million |
| Investments in PPE | -313 Thousand | -348 Thousand | -454.31 Thousand | -429.15 Thousand | -3.34 Million | -7.35 Million |
| Acquisitions | 232 Thousand | - | -493.95 Thousand | - | - | -109.94 Thousand |
| Investment purchases | - | - | - | - | - | -100.00 |
| Sales/Maturities of investments | - | - | - | -402.53 Thousand | - | -629.75 Thousand |
| Other Investing Activities | - | -1.93 Million | -423.19 Thousand | -787.32 Thousand | -1.41 Million | 3.88 Million |
| Financing Cash Flow | 7.5 Million | 13.81 Million | 24.89 Million | 13.64 Million | 10.04 Million | 6.23 Million |
| Debt repayment | -1.23 Million | -266 Thousand | -200.62 Thousand | -2 Million | -12.02 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -699 Thousand | -622 Thousand | -1.43 Million | -1.72 Million | -291.25 Thousand | - |
| Common Stock Issuance | 5.12 Million | 9.96 Million | 26.52 Million | 12.47 Million | 9.83 Million | 3.91 Million |
| Other Financing Activities | 4.31 Million | 4.73 Million | 24.89 Million | 4.9 Million | 12.52 Million | 2.31 Million |
| Accounts receivables | -171 Thousand | -196 Thousand | 465 Thousand | 1.06 Million | -356.87 Thousand | -9795.00 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 4.32 Million | -1.72 Million | 289 Thousand | 883.96 Thousand | -1.54 Million | -442.62 Thousand |
| Other working capital | -19 Thousand | 335 Thousand | 349 Thousand | -1484.00 | 20.3 Thousand | 27.42 Thousand |
| Cash at beginning of period | 1.38 Million | 7.18 Million | 6.04 Million | 2.8 Million | 6.39 Million | 12.42 Million |
| Cash at end of period | 692 Thousand | 1.38 Million | 7.18 Million | 6.04 Million | 2.8 Million | 6.39 Million |
| Capital Expenditure | -313 Thousand | -348 Thousand | -454.31 Thousand | -429.15 Thousand | -3.34 Million | -7.35 Million |
| Effect of forex changes on cash | 21 Thousand | -17 Thousand | -6586.00 | 50.13 Thousand | -124.67 Thousand | 46.46 Thousand |
| Net cash flow / Change in cash | -696 Thousand | -5.79 Million | 1.13 Million | 3.24 Million | -3.59 Million | -6.03 Million |
| Free Cash Flow | -8.45 Million | -17.65 Million | -22.83 Million | -10.05 Million | -13.5 Million | -15.46 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 FY | 2022 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -52.44 Million | -4.94 Million | -18.81 Million | -17.5 Million | -32.78 Million | -4.89 Million |
| Depreciation & Amortization | 2.02 Million | - | 819.18 Thousand | 1.22 Million | 2.57 Million | 103.9 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 7.54 Million | - | - | - | 3.33 Million | - |
| Change in working capital | 4.13 Million | - | - | - | -1.58 Million | - |
| Other non-cash items | 30.59 Million | 3.4 Million | 15.71 Million | 11.02 Million | 11.15 Million | 855.33 Thousand |
| Investing Cash Flow | -81 Thousand | -199.46 Thousand | 141.19 Thousand | 250.12 Thousand | -2.28 Million | -1.82 Million |
| Investments in PPE | -313 Thousand | -151.81 Thousand | -59.94 Thousand | -96.47 Thousand | -348 Thousand | -142.43 Thousand |
| Acquisitions | 232 Thousand | -264.82 Thousand | 413.58 Thousand | 111.74 Thousand | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 217.16 Thousand | -212.45 Thousand | 234.85 Thousand | -1.93 Million | -1.68 Million |
| Financing Cash Flow | 7.5 Million | 1.5 Million | 3.53 Million | 6.27 Million | 13.81 Million | 3.17 Million |
| Debt repayment | -1.23 Million | -2.3 Million | -1.21 Million | -3.04 Million | -266 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -699 Thousand | - | - | - | -622 Thousand | - |
| Common Stock Issuance | 5.12 Million | 648.78 Thousand | 2.31 Million | 3.22 Million | 9.96 Million | 3.17 Million |
| Other Financing Activities | 4.31 Million | 3.15 Million | - | - | 4.73 Million | - |
| Accounts receivables | -171 Thousand | - | - | - | -196 Thousand | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 4.32 Million | - | - | - | -1.72 Million | - |
| Other working capital | -19 Thousand | - | - | - | 335 Thousand | - |
| Cash at beginning of period | 1.38 Million | 717.94 Thousand | 945.76 Thousand | 2.16 Million | 7.18 Million | 5.21 Million |
| Cash at end of period | 692 Thousand | 471.09 Thousand | 717.94 Thousand | 945.76 Thousand | 1.38 Million | 2.16 Million |
| Capital Expenditure | -313 Thousand | -151.81 Thousand | -59.94 Thousand | -96.47 Thousand | -348 Thousand | -142.43 Thousand |
| Effect of forex changes on cash | 21 Thousand | -8577.00 | 16.6 Thousand | -40.68 Thousand | -17 Thousand | -253.01 Thousand |
| Net cash flow / Change in cash | -696 Thousand | -246.84 Thousand | -227.82 Thousand | -1.22 Million | -5.79 Million | -3.04 Million |
| Free Cash Flow | -8.45 Million | -1.69 Million | -3.97 Million | -7.79 Million | -17.65 Million | -4.28 Million |
BREB
CDL
6857
OAMCF
AMNI
VTXPF